recent
peptid
drug
evolv
mainstream
therapeut
repres
signific
portion
pharmaceut
market
howev
bioavail
remain
improv
compar
chemic
drug
screen
identifi
new
peptid
scorpion
venom
peptid
librari
proven
inhibit
hepat
c
viru
hcv
infect
via
inactiv
infecti
viral
particl
howev
suppress
establish
infect
hcv
poor
cellular
uptak
restrict
endosom
base
molecular
templat
peptid
design
two
histidinerich
peptid
significantli
enhanc
cellular
uptak
improv
intracellular
distribut
moreov
two
mutat
peptid
well
wildtyp
peptid
exhibit
virucid
activ
hcv
distinct
contrast
peptid
mutat
peptid
significantli
suppress
establish
hcv
infect
cellular
level
demonstr
lower
cytotox
hemolyt
activ
work
present
effect
design
strategi
optim
natur
antivir
peptid
open
new
avenu
enhanc
bioavail
peptid
drug
recent
peptid
drug
evolv
mainstream
therapeut
repres
signific
portion
pharmaceut
market
peptid
drug
advantag
amen
ration
design
exhibit
highli
divers
structur
broad
biolog
activ
owe
superior
peptid
drug
play
signific
role
therapeut
biomark
howev
mani
obstacl
must
overcom
peptid
drug
appli
clinic
peptid
drug
short
halfliv
system
circul
easili
degrad
proteas
plasma
target
cell
often
easili
clear
reticuloendotheli
system
immunogen
new
synthet
strategi
limit
metabol
altern
rout
administr
emerg
recent
result
numer
peptidebas
drug
market
nevertheless
new
strategi
still
urgent
need
solv
problem
nonspecif
target
poor
uptak
low
effect
biolog
activ
bioavail
famili
peptid
drug
antivir
peptid
attract
much
attent
molecul
display
effect
bioactiv
seri
synthet
antivir
peptid
report
exampl
peptid
deriv
transmembran
glycoprotein
show
potent
inhibit
membran
fusion
viru
entri
clinic
use
patient
despit
therapeut
potenc
resist
strain
emerg
achiev
fusion
inhibit
without
setback
similar
peptid
design
synthes
peptid
effect
even
singl
daili
administr
instead
two
administr
use
retain
activ
strain
anoth
synthet
deriv
peptid
prevent
hcv
infect
inactiv
extraand
intracellular
infecti
particl
potent
antihcv
peptid
destabil
viral
membran
base
lipid
composit
offer
uniqu
therapeut
approach
hcv
type
viral
infect
howev
improv
clinic
use
would
challeng
antivir
peptid
still
face
problem
drug
resist
bioavail
natur
antimicrobi
peptid
amp
provid
plenti
raw
materi
develop
peptid
drug
amp
key
effector
innat
immun
respons
anim
combat
microbi
challeng
thu
far
approxim
eukaryot
amp
isol
molecul
expect
rich
sourc
antibiot
small
peptid
multifunct
effector
innat
immun
skin
mucos
surfac
demonstr
direct
antimicrobi
activ
variou
bacteria
virus
fungi
parasit
natur
amp
scorpion
venom
attract
much
attent
due
antivir
bioactiv
mutat
peptid
shown
virucid
measl
sarsecov
influenza
virus
inhibit
hbv
replic
vitro
vivo
natur
ahel
peptid
proven
properti
kill
hcv
anoth
mutat
peptid
also
effect
inhibit
infect
studi
indic
scorpion
venom
rich
sourc
antivir
peptid
present
new
scorpion
peptid
effici
inhibit
initi
hcv
infect
inactiv
viral
particl
howev
suppress
establish
infect
low
bioavail
result
poor
cellular
uptak
restrict
intracellular
endosom
sinc
addit
histidin
residu
enhanc
helic
amphiphil
endosom
escap
peptid
tri
design
histidinerich
peptid
templat
improv
antivir
activ
cellular
uptak
intracellular
distribut
helic
amphiphil
peptid
character
circular
dichroism
cd
antivir
activ
studi
use
realtim
rtqpcr
confoc
microscopi
assay
use
investig
bioavail
potenti
biotox
peptid
character
measur
cytotox
effect
variou
cell
line
hemolyt
effect
human
red
blood
cell
overal
object
studi
enhanc
bioavail
bioactiv
peptid
drug
overcom
cellular
barrier
chaerilu
tryznai
chaerilu
tricostatu
scorpion
collect
xizang
provinc
china
gland
collect
day
electr
extract
venom
total
rna
prepar
gland
use
trizol
reagent
invitrogen
poli
mrna
purifi
poli
tract
mrna
isol
system
promega
cdna
librari
construct
superscript
plasmid
system
cdna
librari
construct
kit
gibcobrl
cdna
clone
plasmid
gibcobrl
transform
escherichia
coli
cell
randomli
chosen
cdna
clone
sequenc
obtain
reliabl
represent
toxin
content
venom
gland
sequenc
analysi
perform
blastx
program
peptid
classifi
peptid
synthes
use
solidphas
synthesi
method
amid
cterminu
puriti
chinapeptid
co
ltd
china
synthet
peptid
assess
hplc
elitehplc
mass
spectrometri
voyagerdestr
appli
biosystem
secondari
structur
measur
circular
dichroism
cd
spectroscopi
measur
perform
uv
rang
nm
c
water
tfe
use
spectropolarimet
concentr
mgml
spectra
collect
three
separ
record
averag
subtract
blank
spectrum
pure
water
cell
cultur
dulbecco
modifi
eagl
medium
invitrogen
ca
usa
supplement
fetal
bovin
serum
hyclon
penicillin
streptomycin
c
co
incub
hcv
prepar
describ
previous
briefli
viral
stock
dilut
complet
dmem
use
inocul
naiv
confluent
cell
multipl
infect
moi
flask
nest
biotechnolog
co
ltd
china
infect
cell
trypsin
replat
flask
confluenc
day
postinfect
pi
stock
viru
made
collect
filter
supernat
viral
titer
measur
realtim
rtpcr
accord
manufactur
instruct
khb
china
aliquot
store
c
prior
use
cell
seed
sixwel
plate
cell
per
well
next
day
cell
infect
hcv
moi
incub
h
cell
wash
three
time
replenish
growth
medium
h
cell
harvest
detect
total
rna
extract
use
trizol
reagent
transcrib
cdna
use
firststrand
synthesi
supermix
invitrogen
ca
usa
realtim
pcr
perform
use
sybr
green
pcr
assay
abi
system
accord
manufactur
instruct
hcv
gapdh
primer
set
use
mrna
detect
summar
tabl
cell
lyse
radioimmunoprecipit
assay
buffer
mm
trisehcl
ph
mm
sodium
chlorid
nonidet
sodium
deoxychol
phenylmethylsulfonyl
fluorid
concentr
total
protein
determin
use
bca
protein
quantif
kit
equal
amount
protein
electrophores
sodium
dodecyl
sulfatepolyacrylamid
gel
transfer
onto
nitrocellulos
membran
membran
block
incub
skim
milk
primari
antibodi
use
follow
mous
monoclon
antiapo
calbiochem
ger
goat
polyclon
antihcv
abcam
cambridg
uk
mous
monoclon
antihep
c
cag
mous
polyclon
antibactin
santa
cruz
biotechnolog
ca
usa
infect
cell
grown
cell
cultur
flask
viral
protein
analysi
larg
quantiti
cell
cultur
medium
prepar
clear
differenti
centrifug
pass
filter
unit
hcv
particl
medium
concentr
ultracentrifug
rpm
c
h
beckman
rotor
obtain
hcv
pellet
dissolv
pb
treat
peptid
final
concentr
mgml
mixtur
incub
c
h
time
separ
ultracentrifug
supernat
collect
lyophil
protein
hcv
particl
separ
hcv
precipit
supernat
compon
measur
western
blot
analysi
viral
rna
analysi
peptid
dilut
complet
growth
medium
final
concentr
mgml
incub
viru
moi
c
h
point
virusepeptid
mixtur
analyz
hcv
rna
content
infect
compar
control
hcv
rna
content
measur
realtim
rtqpcr
viral
infect
determin
infect
cell
measur
day
later
nterminu
fitclabel
peptid
ad
cell
final
concentr
mgml
incub
c
incub
indic
time
cell
wash
pb
fix
paraformaldehyd
wash
twice
cell
nuclei
stain
dapi
dilut
pb
cell
wash
three
time
pb
cellular
local
peptid
analyz
confoc
microscopi
ca
cq
bafilomycin
supplement
studi
list
chemic
ad
medium
togeth
label
peptid
analyz
cell
seed
plate
cell
per
well
cultur
c
h
seri
concentr
peptid
ad
medium
plate
incub
c
h
time
ml
mtt
solut
mgml
pb
buffer
invitrogen
ad
well
plate
incub
c
h
medium
remov
ml
dmso
ad
plate
shaken
min
room
temperatur
complet
dissolv
crystal
purpl
formazan
absorb
measur
nm
freshli
obtain
human
red
blood
cell
wash
three
time
hepe
buffer
ph
centrifug
min
g
cell
resuspend
salin
seed
plate
cell
per
well
seri
concentr
peptid
ad
incub
c
h
tabl
primer
use
realtim
rtpcr
direct
sequenc
hcv
sens
tcgtatgatacccgatgct
antisens
gtttgacccttgctgttga
gapdh
sens
tgatgacatcaagaaggtggtgaag
antisens
tccttggaggccatgtgggccat
salin
solut
use
neg
control
triton
use
posit
control
plate
centrifug
min
g
absorb
hemoglobin
releas
supernat
measur
nm
data
express
mean
ae
standard
deviat
least
three
separ
experi
statist
signific
test
use
twotail
student
ttest
statist
signific
set
p
extrem
signific
set
p
venom
gland
cdna
librari
scorpion
c
tricostatu
c
tryznai
construct
character
group
sequenc
analysi
peptid
classifi
antimicrobi
peptid
whose
matur
peptid
mostli
includ
amino
acid
residu
fig
matur
peptid
chemic
synthes
screen
abil
inhibit
hcv
infect
cell
fig
rna
analysi
peptid
venom
scorpion
c
tryznai
term
shown
inhibit
hcv
infect
studi
cytotox
cell
test
use
mtt
assay
concentr
inhibit
cell
growth
cc
mgml
concentr
mgml
viabil
peptidetr
cell
greater
indic
mgml
less
minim
cytotox
cell
inhibitori
activ
hcv
infect
timedepend
concentr
fig
treat
h
inhibitori
effect
effect
condit
inhibit
hcv
infect
dosedepend
fig
c
effect
ec
concentr
mgml
investig
whether
inactiv
hcv
particl
viral
supernat
pretreat
h
hcv
rna
content
infect
measur
shown
fig
peptid
reduc
hcv
infect
compar
control
rna
content
hardli
reduc
moreov
sediment
method
use
determin
impact
structur
integr
hcv
particl
briefli
concentr
hcv
particl
incub
without
peptid
h
c
separ
ultracentrifug
viral
structur
protein
supernat
sediment
determin
western
blot
shown
fig
highdens
sediment
without
treatment
contain
high
level
hcv
apo
hcv
core
protein
wherea
supernat
contain
small
amount
protein
treat
level
hcv
apo
protein
significantli
increas
supernat
reduc
sediment
howev
hcv
core
protein
content
hardli
chang
supernat
sediment
data
reveal
peptid
disrupt
membran
integr
hcv
particl
howev
viral
capsid
core
protein
rna
hardli
affect
determin
action
time
mgml
peptid
ad
viru
cell
differ
time
rel
incub
shown
fig
b
display
strong
inhibitori
activ
ad
viru
infect
contrast
much
less
inhibitori
ad
cell
togeth
viru
entir
noninhibitori
ad
cell
h
remov
viru
ad
well
noninhibitori
ad
cell
h
infect
result
suggest
peptid
prevent
initi
hcv
infect
intracellular
antihcv
activ
specul
barrier
infect
cell
restrict
action
peptid
identifi
exact
barrier
cellular
local
determin
confoc
microscopi
shown
fig
label
peptid
slightli
enter
cell
accumul
granular
structur
cytoplasm
result
suggest
poor
cellular
uptak
aggreg
cytoplasm
endosom
restrict
silenc
intracellular
antivir
activ
determin
whether
granular
structur
label
peptid
cytoplasm
gener
endosom
lysosomotrop
agent
chloroquin
ca
ad
analysi
confoc
microscopi
cellular
uptak
peptid
significantli
promot
treatment
mm
chloroquin
mm
ca
fig
intracellular
distribut
improv
dispers
granular
structur
caus
peptid
equal
distribut
cytoplasm
data
clearli
demonstr
lysosomotrop
agent
dramat
enhanc
cellular
uptak
improv
intracellular
distribut
peptid
determin
intracellular
antihcv
effect
lysosomotrop
agent
mm
chloroquin
mm
ca
ad
hcv
infect
show
signific
antivir
effect
hcv
infect
cell
without
chloroquin
ca
fig
howev
produc
signific
reduct
respect
hcv
rna
follow
treatment
chloroquin
ca
compar
treatment
chloroquin
ca
result
indic
intracellular
antihcv
activ
significantli
promot
activ
cellular
uptak
endosom
escap
pathway
onlin
predict
model
show
adopt
ahelix
structur
circular
dichroism
cd
spectroscopi
reveal
adopt
random
coil
structur
water
ahelix
structur
tfe
fig
helic
wheel
exhibit
strong
amphipath
ahelix
conform
hydrophob
face
hydrophil
face
fig
result
suggest
good
dipolar
molecul
form
amphipath
helic
structur
appropri
environ
report
proton
imidazol
group
histidin
residu
play
import
role
endosom
escap
peptid
exhibit
effect
deliveri
function
similar
secondari
structur
peptid
ask
whether
addit
histidin
promot
endosom
escap
base
design
strategi
two
three
histidin
residu
ad
result
deriv
histidinerich
peptid
abbrevi
abbrevi
respect
fig
secondari
structur
predict
determin
abbrevi
wt
shown
fig
c
addit
histidin
residu
disrupt
stabil
secondari
structur
enhanc
amphipath
ahelix
conform
extracellular
antihcv
activ
determin
wildtyp
peptid
briefli
concentr
mg
ml
inhibitori
activ
two
peptid
hcv
infect
occur
timedepend
manner
fig
b
inhibitori
activ
hcv
infect
occur
dosedepend
manner
fig
addit
effect
ec
concentr
mgml
mgml
respect
determin
whether
virucid
hcv
viral
supernat
pretreat
peptid
h
hcv
rna
content
infect
measur
unlik
wildtyp
reduc
viral
rna
respect
although
viral
infect
reduc
similar
peptid
data
suggest
addit
histidin
residu
affect
mode
peptid
action
significantli
enhanc
disrupt
viral
integr
determin
whether
intern
promot
addit
histidin
residu
fitclabel
peptid
use
measur
confoc
microscopi
shown
fig
exhibit
higher
amount
cellular
uptak
wildtyp
specif
exhibit
dispers
distribut
cytoplasm
indic
properti
endosom
escap
base
improv
intracellular
antihcv
activ
determin
three
peptid
ad
h
h
h
postinfect
incub
anoth
h
intracellular
hcv
rna
sampl
measur
shown
fig
three
peptid
exhibit
shown
acidif
endosom
significantli
inhibit
h
atpas
inhibitor
bafilomycin
proton
imidazol
group
histidin
residu
play
import
role
endosom
escap
peptid
exhibit
effect
deliveri
function
howev
inhibit
acidif
endosom
significantli
diminish
deliveri
effici
confirm
endosom
escap
pathway
nm
bafilomycin
ad
cell
togeth
peptid
follow
analysi
confoc
microscopi
shown
fig
cellular
uptak
slightli
reduc
intracellular
distribut
significantli
affect
presenc
bafilomycin
specif
peptid
form
granular
structur
cytoplasm
instead
dispers
equal
distribut
result
demonstr
effici
action
peptid
requir
acidif
endosom
confirm
endosom
escap
pathway
cytotox
activ
mutat
peptid
cell
test
use
mtt
assay
fig
b
hemolysi
activ
also
test
fig
cytotox
concentr
cc
hemolysi
concentr
hc
calcul
shown
tabl
cc
cell
mgml
higher
cc
hc
respect
mgml
mgml
approxim
higher
hc
peptid
mgml
result
indic
antihcv
activ
improv
addit
histidin
residu
also
cytotox
hemolysi
activ
significantli
reduc
although
understand
principl
toxic
improv
detail
design
histidinerich
peptid
exhibit
optim
properti
peptid
drug
includ
bioavail
toxic
fig
studi
screen
new
antihcv
peptid
peptid
librari
scorpion
venom
potent
peptid
whose
ic
mgml
lower
cc
mgml
observ
cell
tabl
select
analysi
display
entir
noteworthi
antivir
mechan
potent
destabil
viral
structur
integr
thu
reduc
initi
hcv
infect
howev
lack
suppress
acquir
infect
poor
cellular
uptak
aggreg
cytoplasm
endosom
therefor
potent
peptid
design
strategi
need
challeng
recent
lysosomotrop
agent
chloroquin
ca
use
enhanc
transfect
effici
peptid
nucleic
acid
pna
peptid
conjug
ca
could
increas
rate
endocytosi
facilit
endosom
releas
specif
increas
interact
conjug
cellular
membran
may
turn
increas
intern
induc
endosom
escap
chloroquin
wellknown
endosomedisrupt
agent
promot
endosom
escap
enhanc
transfect
efficaci
present
studi
also
demonstr
either
mm
chloroquin
mm
ca
significantli
enhanc
cellular
uptak
endosom
escap
promot
intracellular
antivir
activ
result
indic
larg
amount
peptid
remain
entrap
endosom
strategi
improv
low
bioavail
like
involv
cellular
uptak
endosom
escap
pathway
peptid
drug
administr
accompani
addit
lysosomotrop
agent
effect
clinic
practic
past
two
decad
mani
peptid
identifi
properti
caus
cellular
import
cargo
molecul
peptid
collect
call
cellpenetr
peptid
cpp
attract
increas
attent
share
mani
similar
antimicrobi
peptid
interact
disord
cross
cell
membran
cpp
trigger
endocytot
uptak
variou
biomolecul
cell
tatderiv
peptid
influenzaviru
hemagglutinin
protein
elastinlik
polypeptid
elp
artifici
design
peptid
rich
phrespons
histidin
residu
shown
promot
endosom
escap
histidinerich
peptid
shown
exert
peilik
proton
spong
effect
mediat
effect
gene
transfect
activ
also
shown
anoth
histidinerich
peptid
endoport
accord
theori
design
two
histidinerich
peptid
deriv
improv
peptid
bioavail
fig
design
peptid
exhibit
ahelix
structur
wildtyp
peptid
fig
indic
addit
histidin
affect
peptid
structur
enhanc
helic
base
structur
consist
exhibit
effect
virucid
activ
vitro
display
stronger
disrupt
viral
integr
fig
cellular
uptak
significantli
increas
intracellular
distribut
complet
differ
intracellular
distribut
particular
exhibit
dispers
distribut
cytoplasm
indic
properti
endosom
escap
use
treatment
establish
hcv
infect
exhibit
slightli
inhibitori
effect
ad
h
postinfect
much
less
inhibit
ad
h
postinfect
stronger
inhibit
ad
h
postinfect
caus
may
earli
state
infect
matur
viral
particl
cytoplasm
virucid
effect
could
significantli
reflect
howev
hcv
replic
high
level
h
postinfect
intracellular
matur
viral
particl
rapidli
accumul
therefor
mutat
peptid
effect
enter
cell
break
endosom
interact
matur
viral
particl
exhibit
signific
antivir
activ
mechan
enhanc
cellular
uptak
like
involv
addit
histidin
residu
enhanc
modif
stearic
acid
increas
fusion
endosom
membran
high
membran
affin
stearic
acid
mechan
endosom
escap
mostli
includ
interact
peptid
endosom
membran
proton
spong
effect
interact
endosom
membran
histidin
residu
uncharg
neutral
ph
howev
ph
endosom
lumen
drop
imidazol
ring
becom
proton
adopt
inplan
orient
membran
surfac
induc
membran
disord
henc
phinduc
chang
peptid
charg
endosom
acidif
enhanc
abil
escap
endosom
abil
reach
cell
cytosol
andor
eventu
nucleu
ii
proton
spong
effect
proton
induc
extens
inflow
ion
water
endosom
environ
subsequ
lead
osmot
swell
endosom
ruptur
releas
entrap
compon
histidin
residuemedi
endosom
escap
depend
acidif
endosom
inhibit
h
atpas
inhibitor
bafilomycin
determin
ration
action
mode
nm
bafilomycin
use
confoc
analysi
inhibit
acidif
endosom
peptid
accumul
granular
structur
particularli
cytoplasm
similar
shown
fig
result
suggest
interact
intracellular
viral
particl
via
endosom
escap
pathway
interestingli
exhibit
significantli
reduc
cytotox
activ
carcinoma
cell
immort
nonmalign
cell
line
moreov
hemolyt
activ
also
reduc
respect
reduct
like
relat
net
charg
peptid
neutral
ph
net
charg
peptid
wherea
uncharg
posit
charg
may
enhanc
interact
peptid
plasma
membran
caus
higher
disrupt
plasma
membran
thu
uncharg
exhibit
lower
cytotox
hemolyt
activ
howev
specif
mechan
reduc
pharmacolog
toxic
fulli
understood
studi
need
determin
mechan
optim
peptid
could
design
test
multipl
virus
summari
screen
natur
antihcv
peptid
venom
peptid
librari
scorpion
c
tryznai
inactiv
hcv
particl
reduc
viral
infect
howev
suppress
establish
infect
addit
lysosomotrop
agent
chloroquin
ca
significantli
improv
cellular
uptak
intracellular
distribut
thu
promot
antivir
activ
establish
hcv
infect
therefor
design
two
histidinerich
peptid
overcom
cellular
uptak
endosom
barrier
design
fig
schemat
diagram
illustr
mechan
histidinerich
peptid
action
via
cellular
uptak
endosom
escap
pathway
peptid
taken
cell
via
endocytosi
restrict
endosom
acidif
endosom
h
atpas
common
peptid
would
digest
enzym
wherea
endosom
escap
properti
easili
break
endosom
barrier
releas
peptid
cytoplasm
would
target
intracellular
hcv
particl
act
antivir
compound
peptid
exhibit
effect
cellular
uptak
endosom
escap
properti
thu
significantli
reduc
intracellular
viral
level
also
display
lower
pharmacolog
toxic
wildtyp
thu
present
studi
two
histidinerich
peptid
design
possess
intracellular
antivir
activ
first
report
show
optim
bioactiv
peptid
via
cellular
uptak
endosom
escap
pathway
studi
defin
new
optim
strategi
enhanc
bioavail
peptid
drug
